Refractory overactive bladder: Beyond oral anticholinergic therapy.
OBJECTIVE
In this review, we discuss the treatment of refractory overactive bladder (OAB) that has not adequately responded to medication therapy and we propose an appropriate care pathway to the treatment of OAB. We also attempt to address the cost of OAB treatments.


METHODS
A selective expert review of the current literature on the subject of refractory OAB using MEDLINE was performed and the data is summarized. We also review our experience in treating refractory OAB. The role and outcomes of various treatment options for refractory OAB are discussed and combined therapy with oral anticholinergics is explored. Emerging remedies including intravesical botulinum toxin injection and pudendal neuromodulation are also reviewed, along with conventional surgical options.


RESULTS
In general behavioral therapy, pelvic floor electrical stimulation, magnetic therapy and posterior tibial nerve stimulation (PTNS), have shown symptom decreases in 50-80% of patients with OAB. Depending on the study, combination therapy with oral anticholinergics seems to improve efficacy of behavioral therapy and PTNS in approximately 10-30%. In multicenter, long-term randomized controlled trials, sacral neuromodulation has been shown to improve symptoms of OAB and OAB incontinence in up to 80% of the patients treated. Studies involving emerging therapies such as pudendal serve stimulation suggest that there may be a 15-20% increase in efficacy over sacral neuromodulation, but long-term studies are not yet available. Another emerging therapy, botulinum toxin, is also showing similar success in reducing OAB symptoms in 80-90% of patients. Surgical approaches, such as bladder augmentation, are a last resort in the treatment of OAB and are rarely used at this point unless upper tract damage is a concern and all other treatment options have been exhausted.


CONCLUSIONS
The vast majority of OAB patients can be managed successfully by behavioral options with or without anticholinergic medications. When those fail, neuromodulation or intravesical botulinum toxin therapies are successful alternatives for most of the remaining group. We encourage practitioners responsible for the care of OAB patients to gain experience with these options. More research is needed to assess the cost-effectiveness of various OAB treatments.
Glinski
Ronald W
RW
Center for Continence Care and Female Urology, Metro Urology Specialists, 2550 University Avenue West, Suite 240N, St. Paul, MN 55114.
Siegel
Steven
S
Urologe A. 2003 Jun;42(6):819-22
12851774
BJU Int. 2003 Jan;91(1):54-60
12614251
J Urol. 2001 Apr;165(4):1193-8
11257669
Am J Obstet Gynecol. 1948 Aug;56(2):238-48
18877152
Eur Urol. 2006 Mar;49(3):519-27
16413656
Br J Urol. 1987 Jun;59(6):526-8
3690182
J Urol. 2000 Jun;163(6):1849-54
10799197
Urol Clin North Am. 2005 Feb;32(1):109-12
15698883
J Am Med Assoc. 1951 Jul 7;146(10):915-7
14841055
Neurourol Urodyn. 1995;14(1):11-23
7742844
Urology. 2004 Mar;63(3):461-5
15028438
Neurourol Urodyn. 2005;24(4):305-9
15977260
Urology. 1997 Dec;50(6):934-40
9426726
Neurourol Urodyn. 2007;26(1):19-28; discussion 36
17078071
J Urol. 1990 Apr;143(4):671-8
2179579
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005429
16034974
JAMA. 2002 Nov 13;288(18):2293-9
12425706
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005654
16437536
BJU Int. 2006 Mar;97(3):547-50
16469023
J Urol. 2006 Mar;175(3 Pt 1):835-41
16469561
J Urol. 1996 Jan;155(1):127-30
7490809
Acta Obstet Gynecol Scand. 1959;38:487-502
13852819
Tech Urol. 2001 Jun;7(2):126-32
11383990
JAMA. 1998 Dec 16;280(23):1995-2000
9863850
Br J Nurs. 2002 Apr 25-May 8;11(8):560-5
11979209
J Urol. 2001 Jan;165(1):15-9
11125353
BJU Int. 2006 May;97(5):1035-8
16643487
Eur Urol. 2001 Jan;39(1):101-6
11173947
Scand J Urol Nephrol. 2005;39(3):230-3
16118096
J Urol. 2002 Sep;168(3):1044-7
12187219
J Urol. 2006 Jul;176(1):177-85
16753396
Acta Obstet Gynecol Scand Suppl. 1998;168:22-4
9744785
Eur J Obstet Gynecol Reprod Biol. 1995 Nov;63(1):27-30
8674561
J Am Geriatr Soc. 1991 Aug;39(8):785-91
2071809
Urol Clin North Am. 2005 Feb;32(1):89-99
15698881
Mol Med Today. 1996 Oct;2(10):418-24
8897436
J Urol. 2005 May;173(5):1644-6
15821527
J Am Geriatr Soc. 2000 Apr;48(4):370-4
10798461
Br J Urol. 1967 Feb;39(1):3-12
5336762
Microbiol Immunol. 1995;39(3):161-8
7603360
J Urol. 2005 Nov;174(5):1873-7; discussion 1877
16217327
J Urol. 1999 Aug;162(2):352-7
10411037
Neurourol Urodyn. 2005;24(7):643-7
16178000
Urology. 2004 Jun;63(6):1071-5
15183952
J Urol. 1996 Nov;156(5):1744-7
8863585
Neurourol Urodyn. 2003;22(3):227-32
12707873
Tech Urol. 1995 Winter;1(4):181-7
9118389
J Urol. 1989 Aug;142(2 Pt 2):505-8; discussion 520-1
2746767
Int Urogynecol J Pelvic Floor Dysfunct. 2002;13(1):40-3
11999205
Mayo Clin Proc. 2003 Jun;78(6):687-95
12934777
Urol Clin North Am. 2005 Feb;32(1):71-8, vii
15698879
Urology. 2000 Dec 4;56(6 Suppl 1):87-91
11114569
JAMA. 1991 Feb 6;265(5):609-13
1987410
Neurourol Urodyn. 2005;24(3):226-30
15825153
Am J Manag Care. 2005 Jul;11(4 Suppl):S121-9
16161385
Urol Clin North Am. 2005 Feb;32(1):11-8
15698871